Imaging of catecholamine-secreting tumours: uses of MIBG in diagnosis and treatment.
MIBG radiolabelled with 131I or 123I is a radiopharmaceutical which is concentrated in neuroendocrine tumours, particularly phaeochromocytomas and neuroblastomas. This permits non-invasive whole-body scintigraphic screening for benign and malignant, familial and sporadic, intra-adrenal and extra-adrenal phaeochromocytomas and primary and metastatic neuroblastomas, with high sensitivity (85-90%) and specificity (> 95%). MIBG is also concentrated in presynaptic terminals of adrenergic, autonomically innervated organs such as the heart, and may be used as a non-invasive in vivo probe to study this system. Large doses of 131I-MIBG and 125I-MIBG have been used experimentally to selectively deliver therapeutic doses of radiotherapy to malignant phaeochromocytomas and refractory advanced neuroblastomas.
Shapiro
B
B
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor.
D019797:3-Iodobenzylguanidine; D000310:Adrenal Gland Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002395:Catecholamines / Q000378:metabolism*; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D007462:Iodobenzenes / Q000627:therapeutic use*; D009447:Neuroblastoma / Q000000981:diagnostic imaging / Q000378:metabolism / Q000532:radiotherapy; D010673:Pheochromocytoma / Q000000981:diagnostic imaging / Q000378:metabolism / Q000532:radiotherapy; D011877:Radionuclide Imaging
D000970:Antineoplastic Agents; D002395:Catecholamines; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine